Financings Of The Fortnight Hopes 2011 Didn’t Set A (Low) Fundraising Benchmark For 2012
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financings by Warp Drive Bio, Synageva BioPharma, Elevation Pharmaceuticals and Acceleron Pharma.
You may also be interested in...
Seeking Drugs “Hidden In Microbes,” Third Rock Launches Warp Drive Bio
Sanofi has an option to acquire the start-up, which screens for drugs by studying the genomics of natural products – and its investors have an option to force a sale.
With $30 Million Series B In Hand, Elevation Prepares To Take Inhalable COPD Drug Up To Phase III
The two-tranche financing, backed 50% by new investor Novo Ventures, will enable the private firm to evaluate early partnering opportunities from a position of financial stability.
Shire And Atlas Venture To Work Together To Incubate Rare Disease Research Projects
Collaboration will create start-up biotechs to advance promising research in orphan indications, but the companies will not take a “cookie cutter” approach to structure or evolution.